ESC 2022 – factor XI inhibitors crash
Development continues, but multi-billion dollar forecasts for this new anticoagulant class must now be in doubt.
Drug makers leave the pain behind
Developing non-opioid analgesics remains one of the hardest tasks in biopharma.
Can Kalvista make HAE after Pharvaris’s misstep?
A clinical hold for Pharvaris raises questions about the group’s approach, and could leave the door open for its acute rival.
GSK raises more questions about synthetic lethality
Six months on from axing Epizyme’s PRMT-targeting projects GSK says no to Ideaya’s Mat2A work.
Canakinumab’s cancer career ends with a whimper
Novartis's latest failure, in adjuvant lung cancer, heaps more doubt on a rival approach from Cantargia.
